ClinicalTrials.gg
CompletedNCT03390673Updated Jul 29, 2026Results posted

To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects

A Phase 1 interventional study of HD204 and Avastin in Healthy Volunteers, sponsored by Prestige Biopharma Limited. Completed at 2 sites in New Zealand. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Prestige Biopharma Limited · Phase 1, Interventional, and Screening

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The purpose of this study is to compare the pharmacokinetics, as well as to evaluate the safety, tolerability and immunogenicity of HD204, US-Avastin and EU-Avastin in healthy male subjects after intravenous administration of a single dose..

Read the detailed description

This is a double-blind, randomized, three-arm, parallel-group, single-dose study. A total of 120 evaluable subjects are required.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • randomized
  • double-blind
03

In context

Lead sponsor

Prestige Biopharma Limited is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoking healthy male subjects, 18-50 years old inclusive
  • is between 19 to 30 kg/m2, inclusive
  • NO history of or allergic reaction to the active ingredient, murine proteins, or , spontaneous or following drug administration.
  • For subjects with female partners of , an adequate form of must be adhered to prior to entry into the study and for a further 3 months after the end of study. Adequate contraception is defined as the usage by the female partner of any form of hormonal contraception or intra-uterine device (which should be established prior to the start of study) plus usage by one of the partners of an additional spermicide-containing barrier method of contraception. The use of a barrier method alone or reliance on abstinence is not considered adequate.
  • Subjects must agree not to donate sperm during the study and for 4 months following treatment with the study medication or until scheduled End Of Study (EOS), whichever is longer.
  • Subjects must be able to communicate well with the investigator, to understand and comply with the requirements of the study, and understand and sign the written .

Exclusion criteria

Exclusion Criteria:

  • abnormalities in physical examination, laboratory test results or (ECG)
  • Systolic blood pressure > 140 mmHg or \< 90 mmHg , or diastolic blood pressure > 90 mmHg or \<50 mmHg
  • Proteinuria (with a urine dipstick value of 2+ or above)
  • Coagulation abnormalities ( i.e., > 2x )
  • Bleeding diathesis, history of duodenal ulcers, concomitant use of anticoagulants, or any hemorrhage within 6 months prior to study enrollment.
  • Surgical procedure within 2 months of screening, or planned surgical procedure within 2 months of EOS
  • Positive test result for drugs of abuse or alcohol breathing test.
  • Positive test result for surface antigen (HBsAg), (HCV), or (HIV) 1 or 2.
  • Donated or lost > 500ml of blood in the previous 3 months
  • Taken an drug within 3 months (or 5 half-lives), whichever is longer.
  • Taken any prescription medications within 14 days or 5 half-lives (whichever is longer) of the first dose of study drug or non-prescription drugs (with the exception of paracetamol, which is allowed).
  • Previously received bevacizumab or any product considered to be biosimilar to bevacizumab, or any other antibody or protein targeting VEGF or VEGFR.
  • Unwillingness or inability to comply with the study protocol for any reason.
  • Male subject whose partner is pregnant.
  • History or evidence of a clinically significant disorder (including cardiovascular, cerebrovascular, endocrine or psychiatric), or condition, or disease that, in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • History of alcohol and/or drug abuse within 12 months of screening.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    HD204

    Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion

    Drug: HD204

  • Active comparator
    EU-licensed Avastin

    Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion

    Drug: Avastin

  • Active comparator
    US-licensed Avastin

    Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion

    Drug: Avastin

Interventions

  • DrugHD204

    Single-Dose 1mg/kg body weight by 90 minute intravenous infusion

    Also known as: Bevacizumab

  • Single-Dose 1mg/kg body weight by 90 minute intravenous infusion

    Also known as: Bevacizumab

06

What researchers measure

Primary outcomes

  1. Bevacizumab PK Parameter (AUC0-inf)

    PK blood samples were collected from subjects to determine the AUC0-inf of bevacizumab. Samples were collected from 0 (pre-dose) to 1680 (post-dose) on days 1-74.

    Time frame: 71 Days

  2. Serum Concentration of Bevacizumab (AUC0-last)

    PK blood samples were collected from subjects to determine the serum concentration of bevacizumab to evaluate the PK similarity across the three study drugs.

    Time frame: 71 days

  3. Serum Concentration of Bevacizumab (Cmax)

    PK blood samples were collected from subjects to determine the serum concentration of bevacizumab to evaluate the PK similarity across the three study drugs.

    Time frame: 71 days

07

Results

Posted Jun 17, 2026

Participant flow

Healthy subjects, recruited from the IQVIA panel of volunteers, were included in this study.

Participant flow — Overall Study
MilestoneHD204US-licensed AvastinEU-licensed Avastin
Started404039
Completed403938
Not completed011
Withdrew: Withdrawal by subject011

Outcome measures

PrimaryBevacizumab PK Parameter (AUC0-inf)

PK blood samples were collected from subjects to determine the AUC0-inf of bevacizumab. Samples were collected from 0 (pre-dose) to 1680 (post-dose) on days 1-74.

Time frame:
71 Days
Reported as:
Mean · h*mg/L
Bevacizumab PK Parameter (AUC0-inf)
h*mg/LHD204US-licensed AvastinEU-licensed Avastin
Bevacizumab PK Parameter (AUC0-inf)7302.8 ± 1213.67083.6 ± 1164.87062.4 ± 1467.2
Statistical analysis
  • HD204 vs US-licensed Avastin · Geometric mean ratio: 102.95 · 90% CI 96.52 to 109.80
  • HD204 vs US-licensed Avastin · Geometric mean ratio: 103.92 · 90% CI 97.43 to 110.84
  • HD204 vs US-licensed Avastin · Geometric mean ratio: 99.06 · 90% CI 92.92 to 105.61
PrimarySerum Concentration of Bevacizumab (AUC0-last)

PK blood samples were collected from subjects to determine the serum concentration of bevacizumab to evaluate the PK similarity across the three study drugs.

Time frame:
71 days
Reported as:
Mean · h*mg/L
Serum Concentration of Bevacizumab (AUC0-last)
h*mg/LHD204US-licensed AvastinEU-licensed Avastin
Serum Concentration of Bevacizumab (AUC0-last)6969.9 ± 1183.96752.7 ± 1158.66766.8 ± 1455.3
Statistical analysis
  • HD204 vs US-licensed Avastin · Geometric mean ratio: 103.14 · 90% CI 96.52 to 110.20
  • HD204 vs US-licensed Avastin · Geometric mean ratio: 103.59 · 90% CI 96.95 to 110.69
  • US-licensed Avastin vs EU-licensed Avastin · Geometric mean ratio: 99.56 · 90% CI 93.22 to 106.33
PrimarySerum Concentration of Bevacizumab (Cmax)

PK blood samples were collected from subjects to determine the serum concentration of bevacizumab to evaluate the PK similarity across the three study drugs.

Time frame:
71 days
Reported as:
Mean · mg/L
Serum Concentration of Bevacizumab (Cmax)
mg/LHD204US-licensed AvastinEU-licensed Avastin
Serum Concentration of Bevacizumab (Cmax)24.29 ± 4.1822.99 ± 3.4725.59 ± 8.35
Statistical analysis
  • HD204 vs US-licensed Avastin · Geometric mean difference: 105.19 · 90% CI 97.57 to 113.41
  • HD204 vs US-licensed Avastin · Geometric mean ratio: 97.08 · 90% CI 90.05 to 104.67
  • HD204 vs US-licensed Avastin · Geometric mean ratio: 108.36 · 90% CI 100.51 to 116.82

Adverse events

Collected over From the signing of ICF until final visit for the study (Day 71). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HD2040/40 (0%)0/40 (0%)31/40 (77.5%)
US-licensed Avastin0/40 (0%)0/40 (0%)31/40 (77.5%)
EU-licensed Avastin0/39 (0%)0/39 (0%)34/39 (87.2%)
Most frequent other events
Showing 10 of 29
Most frequent other events
EventHD204US-licensed AvastinEU-licensed Avastin
Upper respiratory tract infectionInfections and infestations12/405/408/39
HeadacheNervous system disorders9/407/407/39
Dermatitis contactSkin and subcutaneous tissue disorders2/406/401/39
ContusionInjury, poisoning and procedural complications4/405/404/39
SunburnInjury, poisoning and procedural complications5/400/401/39
Vessel puncture site bruiseGeneral disorders3/402/404/39
LacerationInjury, poisoning and procedural complications4/400/401/39
DizzinessNervous system disorders4/403/401/39
Muscle strainInjury, poisoning and procedural complications0/401/403/39
MyalgiaMusculoskeletal and connective tissue disorders3/402/401/39

Baseline characteristics

Safety Analysis (SA) population - all randomized subjects who received study drug (partial or whole).

Age, Continuous
Age, Continuous(Years)HD204US-licensed AvastinEU-licensed AvastinTotal
Median25.9 (19 to 48)26.0 (18 to 42)25.0 (19 to 50)25.0 (18 to 50)
Sex: Female, Male
Sex: Female, Male(Participants)HD204US-licensed AvastinEU-licensed AvastinTotal
Female0000
Male404039119
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)HD204US-licensed AvastinEU-licensed AvastinTotal
Asian98421
Black or African American1001
Native Hawaiian or other Pacific2024
White27302683
Other12710
08

Study locations

2 sites
  • Auckland Clinical Studies
    Auckland, 1010, New Zealand
  • Christchurch Clinical Studies Trust Ltd
    Christchurch, 8011, New Zealand
09

References and documents

Publications

  • Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X. A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab. PLoS One. 2021 Sep 23;16(9):e0248222. doi: 10.1371/journal.pone.0248222. eCollection 2021. PubMed 34555031 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Mar 2019, 5 months.

Results were first posted in Jun 2026, 7 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2017
First posted
Jan 4, 2018
StartActual
Sep 19, 2018
Primary completionActual
Mar 13, 2019
CompletionActual
Mar 13, 2019
Results first posted
Jun 17, 2026
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03390673
Lead sponsor
Prestige Biopharma Limited
Responsible party
Sponsor
First posted
Jan 4, 2018
Start date
Sep 19, 2018
Primary completion
Mar 13, 2019
Completion
Mar 13, 2019
Results posted
Jun 17, 2026
Last update
Jul 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion